The absence of detailed classification of the adverse outcomes, the lack of adjustment for significant confounders like smoking and hyperlipidemia, and potential confounding by indication, especially in patients with pre-existing diabetes versus those using GLP-1 RAs for weight loss, are notable limitations that future research should aim to address. This evidence concerns the gene GCG and hyperlipidemia.